{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T01:37:04Z","timestamp":1760146624989,"version":"build-2065373602"},"reference-count":70,"publisher":"MDPI AG","issue":"6","license":[{"start":{"date-parts":[[2024,11,25]],"date-time":"2024-11-25T00:00:00Z","timestamp":1732492800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Project COVID management and acquired immunity assessment in the IPL community (COVIDVax_IPL) funded by Instituto Polit\u00e9cnico de Lisboa (IPL)"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Infectious Disease Reports"],"abstract":"<jats:p>Background\/Objectives: The COVID-19 pandemic has revolutionized vaccine production and compelled a massive global vaccination campaign. This study aimed to estimate the positivity and levels of SARS-CoV-2 IgG antibodies acquired due to vaccination and infection in the academic population of a Portuguese university. Methods: Blood samples were collected and analyzed through the ELISA methodology, and statistical analysis was performed. Results: A total of 529 volunteers with at least one dose of the vaccine were enrolled in this study. Individuals without a prior COVID-19 diagnosis were divided into two groups: 350, who received a full vaccination, and 114, who received a full vaccination and a booster dose of the same vaccine (81) and mixed vaccines (33). Regarding the individuals who reported a prior SARS-CoV-2 infection, 31 received a full vaccination, and 34 received only one vaccination dose. Data analysis showed a higher level of IgG against SARS-CoV-2 in individuals who were younger, female, who received the Moderna vaccine, with recent post-vaccine administration, a mixed booster dose, and prior SARS-CoV-2 infection. Conclusions: Assessing vaccination\u2019s effectiveness and group immunity is crucial for pandemic management, particularly in academic environments with high individual mobility, in order to define groups at risk and redirect infection control strategies.<\/jats:p>","DOI":"10.3390\/idr16060088","type":"journal-article","created":{"date-parts":[[2024,11,26]],"date-time":"2024-11-26T05:06:53Z","timestamp":1732597613000},"page":"1084-1097","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["SARS-CoV-2 Immunization Index in the Academic Community: A Retrospective Post-Vaccination Study"],"prefix":"10.3390","volume":"16","author":[{"given":"Keltyn","family":"Oliveira","sequence":"first","affiliation":[{"name":"Health & Technology Research Center, Escola Superior de Tecnologia da Sa\u00fade, Instituto Polit\u00e9cnico de Lisboa, Av. D. Jo\u00e3o II, Lote 4.69.01, Parque das Na\u00e7\u00f5es, 1990-096 Lisboa, Portugal"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1662-796X","authenticated-orcid":false,"given":"Ana","family":"Almeida","sequence":"additional","affiliation":[{"name":"Escola Superior de Tecnologia da Sa\u00fade, Instituto Polit\u00e9cnico de Lisboa, Av. D. Jo\u00e3o II, Lote 4.69.01, Parque das Na\u00e7\u00f5es, 1990-096 Lisboa, Portugal"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1021-7935","authenticated-orcid":false,"given":"Carina","family":"Silva","sequence":"additional","affiliation":[{"name":"Health & Technology Research Center, Escola Superior de Tecnologia da Sa\u00fade, Instituto Polit\u00e9cnico de Lisboa, Av. D. Jo\u00e3o II, Lote 4.69.01, Parque das Na\u00e7\u00f5es, 1990-096 Lisboa, Portugal"},{"name":"Centro de Estat\u00edstica e Aplica\u00e7\u00f5es, Faculdade de Ci\u00eancias, Universidade de Lisboa, 1749-016 Lisboa, Portugal"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6394-658X","authenticated-orcid":false,"given":"Miguel","family":"Brito","sequence":"additional","affiliation":[{"name":"Health & Technology Research Center, Escola Superior de Tecnologia da Sa\u00fade, Instituto Polit\u00e9cnico de Lisboa, Av. D. Jo\u00e3o II, Lote 4.69.01, Parque das Na\u00e7\u00f5es, 1990-096 Lisboa, Portugal"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1316-7750","authenticated-orcid":false,"given":"Edna","family":"Ribeiro","sequence":"additional","affiliation":[{"name":"Health & Technology Research Center, Escola Superior de Tecnologia da Sa\u00fade, Instituto Polit\u00e9cnico de Lisboa, Av. D. Jo\u00e3o II, Lote 4.69.01, Parque das Na\u00e7\u00f5es, 1990-096 Lisboa, Portugal"}]}],"member":"1968","published-online":{"date-parts":[[2024,11,25]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1056\/NEJMoa2001017","article-title":"A Novel Coronavirus from Patients with Pneumonia in China, 2019","volume":"382","author":"Zhu","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"660","DOI":"10.1128\/CMR.00023-07","article-title":"Severe Acute Respiratory Syndrome Coronavirus as an Agent of Emerging and Reemerging Infection","volume":"20","author":"Cheng","year":"2007","journal-title":"Clin. Microbiol. Rev."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"536","DOI":"10.1038\/s41564-020-0695-z","article-title":"The species Severe acute respiratory syndrome-related coronavirus: Classifying 2019-nCoV and naming it SARS-CoV-2","volume":"5","author":"Gorbalenya","year":"2020","journal-title":"Nat. Microbiol."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1038\/s41579-022-00713-0","article-title":"SARS-CoV-2 pathogenesis","volume":"20","author":"Lamers","year":"2022","journal-title":"Nat. Rev. Microbiol."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"1478","DOI":"10.3201\/eid2607.200841","article-title":"Severe Acute Respiratory Syndrome Coronavirus 2-Specific Antibody Responses in Coronavirus Disease Patients","volume":"26","author":"Okba","year":"2020","journal-title":"Emerg. Infect. Dis."},{"key":"ref_6","doi-asserted-by":"crossref","unstructured":"Amanat, F., Stadlbauer, D., Strohmeier, S., Nguyen, T.H.O., Chromikova, V., McMahon, M., Jiang, K., Asthagiri Arunkumar, G., Jurczyszak, D., and Polanco, J. (2020). A serological assay to detect SARS-CoV-2 seroconversion in humans. medRxiv.","DOI":"10.1101\/2020.03.17.20037713"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"915","DOI":"10.4049\/jimmunol.2000583","article-title":"A Potently Neutralizing Antibody Protects Mice against SARS-CoV-2 Infection","volume":"205","author":"Alsoussi","year":"2020","journal-title":"J. Immunol."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1038\/s41586-020-2571-7","article-title":"Potent neutralizing antibodies against multiple epitopes on SARS-CoV-2 spike","volume":"584","author":"Liu","year":"2020","journal-title":"Nature"},{"key":"ref_9","unstructured":"Our World in Data (2022, June 29). Coronavirus (COVID-19) Cases. Available online: https:\/\/ourworldindata.org\/covid-cases."},{"key":"ref_10","unstructured":"Our World in Data (2022, June 29). Coronavirus (COVID-19) Deaths. Available online: https:\/\/ourworldindata.org\/covid-deaths."},{"key":"ref_11","doi-asserted-by":"crossref","unstructured":"Eurosurveillance editorial team (2020). Note from the editors: World Health Organization declares novel coronavirus (2019-nCoV) sixth public health emergency of international concern. Eurosurveillance, 25, 200131e.","DOI":"10.2807\/1560-7917.ES.2020.25.5.200131e"},{"key":"ref_12","doi-asserted-by":"crossref","unstructured":"Milhinhos, A., and Costa, P.M. (2020). On the Progression of COVID-19 in Portugal: A Comparative Analysis of Active Cases Using Non-linear Regression. Front. Public Health, 8.","DOI":"10.3389\/fpubh.2020.00495"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1111\/all.14657","article-title":"Risk factors for severe and critically ill COVID-19 patients: A review","volume":"76","author":"Gao","year":"2021","journal-title":"Allergy"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"1227","DOI":"10.1126\/science.abd7728","article-title":"Robust neutralizing antibodies to SARS-CoV-2 infection persist for months","volume":"370","author":"Wajnberg","year":"2020","journal-title":"Science"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1128\/JCM.02107-20","article-title":"Neutralizing Antibodies Correlate with Protection from SARS-CoV-2 in Humans during a Fishery Vessel Outbreak with a High Attack Rate","volume":"58","author":"Addetia","year":"2020","journal-title":"J. Clin. Microbiol."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"e6","DOI":"10.1016\/S0140-6736(20)31484-7","article-title":"Pandemic peak SARS-CoV-2 infection and seroconversion rates in London frontline health-care workers","volume":"396","author":"Houlihan","year":"2020","journal-title":"Lancet"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"1595","DOI":"10.1016\/S0140-6736(20)32137-1","article-title":"SARS-CoV-2 immunity: Review and applications to phase 3 vaccine candidates","volume":"396","author":"Poland","year":"2020","journal-title":"Lancet"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"1925","DOI":"10.15585\/mmwr.mm6950e3","article-title":"Factors Associated with Positive SARS-CoV-2 Test Results in Outpatient Health Facilities and Emergency Departments Among Children and Adolescents Aged","volume":"69","author":"Hobbs","year":"2020","journal-title":"MMWR Morb. Mortal. Wkly. Rep."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"e2020048090","DOI":"10.1542\/peds.2020-048090","article-title":"Incidence and Secondary Transmission of SARS-CoV-2 Infections in Schools","volume":"147","author":"Zimmerman","year":"2021","journal-title":"Pediatrics"},{"key":"ref_20","first-page":"2001352","article-title":"A large COVID-19 outbreak in a high school 10 days after schools\u2019 reopening, Israel, May 2020","volume":"25","author":"Abramson","year":"2020","journal-title":"Eurosurveillance"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"113038","DOI":"10.1016\/j.envres.2022.113038","article-title":"The role of outdoor and indoor air quality in the spread of SARS-CoV-2: Overview and recommendations by the research group on COVID-19 and particulate matter (RESCOP commission)","volume":"211","author":"Piscitelli","year":"2022","journal-title":"Environ. Res."},{"key":"ref_22","unstructured":"European Medicines Agency (2022, June 30). COVID-19 Vaccines: Authorised. Available online: https:\/\/www.ema.europa.eu\/en\/human-regulatory\/overview\/public-health-threats\/coronavirus-disease-covid-19\/treatments-vaccines\/vaccines-covid-19\/covid-19-vaccines-authorised."},{"key":"ref_23","unstructured":"Our World in Data (2022, June 30). Coronavirus (COVID-19) Vaccinations. Available online: https:\/\/ourworldindata.org\/covid-vaccinations."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"2603","DOI":"10.1056\/NEJMoa2034577","article-title":"Safety and Efficacy of the BNT162b2 mRNA COVID-19 Vaccine","volume":"383","author":"Polack","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1056\/NEJMoa2035389","article-title":"Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine","volume":"384","author":"Baden","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1016\/S0140-6736(20)32661-1","article-title":"Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: An interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK","volume":"397","author":"Voysey","year":"2021","journal-title":"Lancet"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"2187","DOI":"10.1056\/NEJMoa2101544","article-title":"Safety and Efficacy of Single-Dose Ad26.COV2.S Vaccine against COVID-19","volume":"384","author":"Sadoff","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"ref_28","unstructured":"Centers for Disease Control and Prevention (2022, July 05). COVID-19 Vaccines are Effective, Available online: https:\/\/www.cdc.gov\/covid\/vaccines\/covid-19-vaccine-effectiveness.html."},{"key":"ref_29","unstructured":"World Health Organization (2022, July 05). Vaccine Efficacy, Effectiveness and Protection. Available online: https:\/\/www.who.int\/news-room\/feature-stories\/detail\/vaccine-efficacy-effectiveness-and-protection."},{"key":"ref_30","doi-asserted-by":"crossref","unstructured":"Hall, V., Foulkes, S., Charlett, A., Atti, A., Monk, E., Simmons, R., Wellington, E., Cole, M., Saei, A., and Oguti, B. (2021). Do Antibody Positive Healthcare Workers Have Lower SARS-CoV-2 Infection Rates than Antibody Negative Healthcare Workers? Large Multi-Centre Prospective Cohort Study (the SIREN Study), England: June to November 2020. Medrxiv.","DOI":"10.1101\/2021.01.13.21249642"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1056\/NEJMoa2034545","article-title":"Antibody Status and Incidence of SARS-CoV-2 Infection in Health Care Workers","volume":"384","author":"Lumley","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"eade9078","DOI":"10.1126\/scitranslmed.ade9078","article-title":"Comparing antibody assays as correlates of protection against COVID-19 in the COVE mRNA-1273 vaccine efficacy trial","volume":"15","author":"Benkeser","year":"2024","journal-title":"Sci. Transl. Med."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"4423","DOI":"10.1016\/j.vaccine.2021.05.063","article-title":"Evidence for antibody as a protective correlate for COVID-19 vaccines","volume":"39","author":"Earle","year":"2021","journal-title":"Vaccine"},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1038\/s41586-021-03207-w","article-title":"Evolution of antibody immunity to SARS-CoV-2","volume":"591","author":"Gaebler","year":"2021","journal-title":"Nature"},{"key":"ref_35","doi-asserted-by":"crossref","unstructured":"Post, N., Eddy, D., Huntley, C., van Schalkwyk, M.C.I., Shrotri, M., Leeman, D., Rigby, S., Williams, S.V., Bermingham, W.H., and Kellam, P. (2020). Antibody response to SARS-CoV-2 infection in humans: A systematic review. PLoS ONE, 15.","DOI":"10.1101\/2020.08.25.20178806"},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"791","DOI":"10.1099\/jgv.0.001439","article-title":"The dynamics of humoral immune responses following SARS-CoV-2 infection and the potential for reinfection","volume":"101","author":"Kellam","year":"2020","journal-title":"J. Gen. Virol."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"327","DOI":"10.3201\/eid2701.203515","article-title":"Waning Antibody Responses in Asymptomatic and Symptomatic SARS-CoV-2 Infection","volume":"27","author":"Choe","year":"2021","journal-title":"Emerg. Infect. Dis."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"1951","DOI":"10.1007\/s11845-021-02799-6","article-title":"Pre-vaccination immune response to COVID-19 in a population in Northeast Portugal","volume":"191","author":"Duro","year":"2022","journal-title":"Ir. J. Med. Sci."},{"key":"ref_39","doi-asserted-by":"crossref","unstructured":"Keshavarz, B., Richards, N.E., Workman, L.J., Patel, J., Muehling, L.M., Canderan, G., Murphy, D.D., Brovero, S.G., Ailsworth, S.M., and Eschenbacher, W.H. (2022). Trajectory of IgG to SARS-CoV-2 After Vaccination with BNT162b2 or mRNA-1273 in an Employee Cohort and Comparison with Natural Infection. Front. Immunol., 13.","DOI":"10.3389\/fimmu.2022.850987"},{"key":"ref_40","doi-asserted-by":"crossref","unstructured":"Hagiya, H., Nakano, Y., Furukawa, M., Sunada, N., Hasegawa, T., Sakurada, Y., Hasegawa, K., Yamamoto, K., Ogawa, H., and Obara, T. (2022). Early-stage antibody kinetics after the third dose of BNT162b2 mRNA COVID-19 vaccination measured by a point-of-care fingertip whole blood testing. Sci. Rep., 12.","DOI":"10.1038\/s41598-022-24464-3"},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"3674","DOI":"10.1038\/s41467-021-23938-8","article-title":"Controlling the pandemic during the SARS-CoV-2 vaccination rollout","volume":"12","author":"Viana","year":"2021","journal-title":"Nat. Commun."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"1147","DOI":"10.1038\/s41591-021-01432-4","article-title":"A correlate of protection for SARS-CoV-2 vaccines is urgently needed","volume":"27","author":"Krammer","year":"2021","journal-title":"Nat. Med."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1038\/d41586-020-03626-1","article-title":"The lightning-fast quest for COVID vaccines\u2014And what it means for other diseases","volume":"589","author":"Ball","year":"2021","journal-title":"Nature"},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"1342","DOI":"10.1016\/j.jiac.2021.06.008","article-title":"Epidemiological study using IgM and IgG antibody titers against SARS-CoV-2 in The University of Tokyo, Japan (UT-CATS)","volume":"27","author":"Mitani","year":"2021","journal-title":"J. Infect. Chemother."},{"key":"ref_45","doi-asserted-by":"crossref","unstructured":"Lee, C.C., Segaloff, H.E., Cole, D., Rosenblum, H.G., Morgan, C.N., Somers, T., Desamu-Thorpe, R., Foster, M.A., Currie, D., and Ruff, J. (2022). A cohort study measuring SARS-CoV-2 seroconversion and serial viral testing in university students. BMC Infect. Dis., 22.","DOI":"10.1186\/s12879-022-07314-5"},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"907","DOI":"10.1038\/s41467-022-28527-x","article-title":"Population antibody responses following COVID-19 vaccination in 212,102 individuals","volume":"13","author":"Ward","year":"2022","journal-title":"Nat. Commun."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"100928","DOI":"10.1016\/j.eclinm.2021.100928","article-title":"Initial observations on age, gender, BMI and hypertension in antibody responses to SARS-CoV-2 BNT162b2 vaccine","volume":"36","author":"Pellini","year":"2021","journal-title":"EClinicalMedicine"},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"5350","DOI":"10.1016\/j.vaccine.2017.07.062","article-title":"Personalized vaccinology: A review","volume":"36","author":"Poland","year":"2018","journal-title":"Vaccine"},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1146\/annurev-cellbio-100616-060718","article-title":"Sex and Gender Differences in the Outcomes of Vaccination over the Life Course","volume":"33","author":"Flanagan","year":"2017","journal-title":"Annu. Rev. Cell Dev. Biol."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1016\/S1473-3099(10)70049-9","article-title":"The Xs and Y of immune responses to viral vaccines","volume":"10","author":"Klein","year":"2010","journal-title":"Lancet Infect. Dis."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"1140","DOI":"10.1038\/s41564-021-00947-3","article-title":"Antibody responses to SARS-CoV-2 vaccines in 45,965 adults from the general population of the United Kingdom","volume":"6","author":"Wei","year":"2021","journal-title":"Nat. Microbiol."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"868","DOI":"10.1001\/jama.2021.11656","article-title":"Age-Dependent Neutralization of SARS-CoV-2 and P.1 Variant by Vaccine Immune Serum Samples","volume":"326","author":"Bates","year":"2021","journal-title":"JAMA"},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"2065","DOI":"10.1093\/cid\/ciab381","article-title":"Age-dependent Immune Response to the Biontech\/Pfizer BNT162b2 Coronavirus Disease 2019 Vaccination","volume":"73","author":"Moskorz","year":"2021","journal-title":"Clin. Infect. Dis."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1016\/j.arr.2010.08.004","article-title":"Age effects on B cells and humoral immunity in humans","volume":"10","author":"Frasca","year":"2011","journal-title":"Ageing Res. Rev."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"5416","DOI":"10.1002\/jmv.27059","article-title":"Determinants of IgG antibodies kinetics after severe and critical COVID-19","volume":"93","author":"Scohy","year":"2021","journal-title":"J. Med. Virol."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"1614","DOI":"10.1038\/s41467-022-29225-4","article-title":"Modeling of waning immunity after SARS-CoV-2 vaccination and influencing factors","volume":"13","author":"Armenteros","year":"2022","journal-title":"Nat. Commun."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"e84","DOI":"10.1056\/NEJMoa2114583","article-title":"Waning Immune Humoral Response to BNT162b2 COVID-19 Vaccine over 6 Months","volume":"385","author":"Levin","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"e83","DOI":"10.1056\/NEJMoa2114114","article-title":"Waning of BNT162b2 Vaccine Protection against SARS-CoV-2 Infection in Qatar","volume":"385","author":"Chemaitelly","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"744","DOI":"10.1056\/NEJMoa2116597","article-title":"Effect of COVID-19 Vaccination on Transmission of Alpha and Delta Variants","volume":"386","author":"Eyre","year":"2022","journal-title":"N. Engl. J. Med."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"1700","DOI":"10.15585\/mmwr.mm7049a2","article-title":"Comparative Effectiveness and Antibody Responses to Moderna and Pfizer-BioNTech COVID-19 Vaccines among Hospitalized Veterans\u2014Five Veterans Affairs Medical Centers, United States, February 1\u2013September 30, 2021","volume":"70","author":"Bajema","year":"2021","journal-title":"MMWR Morb. Mortal. Wkly. Rep."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"1533","DOI":"10.1001\/jama.2021.15125","article-title":"Comparison of SARS-CoV-2 Antibody Response Following Vaccination with BNT162b2 and mRNA-1273","volume":"326","author":"Steensels","year":"2021","journal-title":"JAMA"},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"E297","DOI":"10.1503\/cmaj.211881","article-title":"Differences in mRNA-1273 (Moderna) and BNT162b2 (Pfizer-BioNTech) SARS-CoV-2 vaccine immunogenicity among patients undergoing dialysis","volume":"194","author":"Yau","year":"2022","journal-title":"CMAJ"},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"1365","DOI":"10.1136\/annrheumdis-2021-221145","article-title":"Antibody response to the Janssen\/Johnson & Johnson SARS-CoV-2 vaccine in patients with rheumatic and musculoskeletal diseases","volume":"80","author":"Chiang","year":"2021","journal-title":"Ann. Rheum. Dis."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"e82","DOI":"10.1097\/TP.0000000000003850","article-title":"Antibody Response to the Janssen COVID-19 Vaccine in Solid Organ Transplant Recipients","volume":"105","author":"Boyarsky","year":"2021","journal-title":"Transplantation"},{"key":"ref_65","doi-asserted-by":"crossref","unstructured":"Benning, L., T\u00f6llner, M., Hidmark, A., Schaier, M., Nusshag, C., K\u00e4lble, F., Reichel, P., Buylaert, M., Grenz, J., and Ponath, G. (2021). Heterologous ChAdOx1 nCoV-19\/BNT162b2 Prime-Boost Vaccination Induces Strong Humoral Responses among Health Care Workers. Vaccines, 9.","DOI":"10.3390\/vaccines9080857"},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"1530","DOI":"10.1038\/s41591-021-01464-w","article-title":"Immunogenicity and reactogenicity of heterologous ChAdOx1 nCoV-19\/mRNA vaccination","volume":"27","author":"Schmidt","year":"2021","journal-title":"Nat. Med."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1016\/S0140-6736(21)01420-3","article-title":"Immunogenicity and reactogenicity of BNT162b2 booster in ChAdOx1-S-primed participants (CombiVacS): A multicentre, open-label, randomised, controlled, phase 2 trial","volume":"398","author":"Borobia","year":"2021","journal-title":"Lancet"},{"key":"ref_68","doi-asserted-by":"crossref","unstructured":"DeJonge, P.M., Lambrou, A.S., Segaloff, H.E., Bateman, A., Sterkel, A., Griggs, C., Baggott, J., Kelly, P., Thornburg, N., and Epperson, M. (2023). Assessment of Anti-SARS-CoV-2 antibody levels among university students vaccinated with different COVID-19 primary and booster doses\u2014Fall 2021, Wisconsin. BMC Infect. Dis., 23.","DOI":"10.1186\/s12879-023-08332-7"},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"2127","DOI":"10.1038\/s41591-021-01548-7","article-title":"Effect of Delta variant on viral burden and vaccine effectiveness against new SARS-CoV-2 infections in the UK","volume":"27","author":"Pouwels","year":"2021","journal-title":"Nat. Med."},{"key":"ref_70","doi-asserted-by":"crossref","unstructured":"Ali, H., Alahmad, B., Al-Shammari, A.A., Alterki, A., Hammad, M., Cherian, P., Alkhairi, I., Sindhu, S., Thanaraj, T.A., and Mohammad, A. (2021). Previous COVID-19 Infection and Antibody Levels After Vaccination. Front. Public Health, 9.","DOI":"10.3389\/fpubh.2021.778243"}],"container-title":["Infectious Disease Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2036-7449\/16\/6\/88\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T16:39:13Z","timestamp":1760114353000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2036-7449\/16\/6\/88"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,11,25]]},"references-count":70,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["idr16060088"],"URL":"https:\/\/doi.org\/10.3390\/idr16060088","relation":{},"ISSN":["2036-7449"],"issn-type":[{"type":"electronic","value":"2036-7449"}],"subject":[],"published":{"date-parts":[[2024,11,25]]}}}